To create value through the development and commercialisation of innovative products for airways diseases with high unmet needs.
Vectura is a respiratory product development Company. Enabled by our high-quality proprietary technologies, our experienced employees work hard to ensure we continue to be one of the leading names within our sector.
14 Apr 2015
Gemünden - Planned Closure
01 Apr 2015
Appointment of non-executive director
17 Apr 2015
Notification of Transactions of Directors
16 Apr 2015
Block Listing Return
Our product portfolio comprises marketed products, which provide an important source of revenue; branded investigational drugs, at different stages of development with partners or by Vectura alone; and generic investigational drugs.
View our product pipeline
Annual Report and Accounts for Year Ended 31 March 2014
View online report
Vectura signs global development and licence agreement with Janssen in asthma/COPD
Chippenham, UK – 6 January 2015: Vectura Group plc (LSE: VEC; "Vectura" or the "Company") today announced that the company has entered into a global development and licence agreement with Janssen Biotech, Inc. ("Janssen") for the exclusive development of novel anti-inflammatory therapies for the treatment of asthma/COPD. The collaboration will focus initially on the development of a Phase II candidate and has the potential to include additional clinical-stage candidates.
Share price details
Final results for year ending 31 March 2015
Annual General Meeting
Stay informed Register to our news alert and receive latest updates on news and events
For general enquiries, call us on +44 (0)1249 667700. For more specific enquiries, visit Contact us
Most computers will open PDF documents automatically, but you may need to download Adobe Reader.